RxDoctor Payments Data

Nicole Higashiyama

Internal Medicine · Los Angeles, CANPI 1609294024

Payments from drug & device makers

$1,386in general payments, 2019–2025

Across 87 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$308
  • AstraZeneca$162
  • Bayer$143
  • E.r. Squibb & Sons, L.L.C.$139
  • Pfizer$132
  • Takeda Pharmaceuticals U.S.A., Inc.$102
  • plus $400 from 10 others

What the payments were for

  • Food & beverage$1,29894%
  • Education$886%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,386 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$75,682
Medicare patients
25
Services billed
2,679

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate49$842,674
IbrancePalbociclib38$585,937
XtandiEnzalutamide44$484,963
Lenalidomide38$377,026
PomalystPomalidomide12$297,412
CabometyxCabozantinib S-Malate14$292,820
OrserduElacestrant Hcl13$276,676
AlecensaAlectinib Hcl12$241,549
CalquenceAcalabrutinib Maleate18$193,838
GilotrifAfatinib Dimaleate15$191,802
VerzenioAbemaciclib11$143,485
AlvaizEltrombopag Choline12$92,837
EliquisApixaban21$32,212
ZenpepLipase/Protease/Amylase16$28,001
NivestymFilgrastim-Aafi19$15,247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso, Calquence$162$1,036,51267 claims
PfizerIbrance, Eliquis, Nivestym$132$633,39578 claims
Astellas Pharma US IncXtandi$22$484,96344 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$139$297,41212 claims
Lilly USA, LLCVerzenio$87$143,48511 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$17$63231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →